1000 chemin du GolfVerdun,
H3E 1H4
Canada
Phone: (514) 751-2003
E-Mail: cpanchal@ambrilia.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Description:
Biopharmaceutical company developing early to mid-stage therapeutics in the fields of oncology and infectious diseases. Product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a Tumor Vasculature Targeting (TVT) technology platform, an improved, prolonged release formulation of Octreotide, a new formulation of Goserelin and promising anti-HIV treatments (PPL-100, Integrase Inhibitor Program).